莱美药业：预计2025年亏损1.2亿元～1.35亿元

Core Viewpoint - The company expects a net profit loss attributable to shareholders of 120 million to 135 million yuan for the year 2025, compared to a loss of 87.8044 million yuan in the same period last year [1] Financial Performance - The net profit loss after deducting non-recurring gains and losses is anticipated to be between 124 million and 139 million yuan, compared to a loss of 119 million yuan in the previous year [1] - The performance fluctuation is primarily due to a decline in sales volume and prices of certain products, leading to a slight decrease in operating revenue year-on-year [1] Investment and Impairment - Continuous research and development investments are impacting operating profits [1] - The company has recognized an impairment provision for certain intangible assets amounting to approximately 60 million yuan [1] - An investment loss of about 23 million yuan has also been confirmed [1]